Novartis
Basel, Switzerland
East Hanover, New Jersey, United States
with other locations globally
United States
Website: https://www.novartis.com/
2123 articles with Novartis
-
Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
3/8/2022
Voyager Therapeutics, Inc. announced an agreement through which Novartis may exercise options to license novel AAV capsids generated from Voyager’s RNA-driven TRACERTM capsid discovery platform for potential use with three undisclosed CNS targets and options to access capsids for two additional targets to be agreed on in the future.
-
Voyager has partnered with Novartis for the latter to use the gene therapy company's capsid discovery platform to create new treatments for three undisclosed CNS targets.
-
A new market research report by InsightAce Analytic projects the immuno-oncology or cancer immunotherapy market will hit $34.69 billion by 2030.
-
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
-
GlaxoSmithKline unveiled plans for its new spinout in the consumer health division, Haleon. It is expected to be in place by mid-2022.
-
Prescription drug costs have continued to rise, with more than 150 drug manufacturers raising their prices in January.
-
Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors
2/16/2022
Cambrian Biopharma today announced a licensing agreement with Novartis to advance novel, selective compounds designed and characterized by Novartis to target the mechanistic target of rapamycin (mTOR) pathway.
-
The EUA request is based on the Phase II study that showed treatment with ensovibep reduced the viral load from the SARS-CoV-2 virus within eight days of use compared to placebo.
-
The COVID-19 pandemic has seen a full-blown effort from biopharma and researchers to develop new drugs and test old ones against the disease, with highly mixed results.
-
The FDA is slowing down the process of potentially approving dozens of new medications initially developed for the Chinese market.
-
Novartis CEO Vas Narasimhan and Roche CEO Severin Schwan saw revenue growth for the past year, and each took home more than $12 million in total compensation for 2021.
-
Novartis reported its full-year financials this week for 2021, and overall, the news was good. Of concern, however, is the company’s Sandoz generics unit.
-
J&J said it was terminating development of bermekimab for atopic dermatitis after looking at additional efficacy data.
-
Even as Novartis entertains the potential sale of Sandoz, the company is lauding growth in its biosimilars business that is expected to stabilize its future development.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Clinical Catch-Up: January 10-14
1/17/2022
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look. -
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
-
The U.S. averages more than 700,000 new COVID-19 cases per day. As of Saturday, there were 4.91M cases, more cases in seven days than in April, May, June, and July 2021 combined.
-
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
1/6/2022
Alnylam Pharmaceuticals, Inc. today announced a collaboration with Novartis to leverage Alnylam’s proven, proprietary siRNA technology.
-
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.